{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:57:38Z","timestamp":1780088258325,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.humpath.2025.105792","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:59:53Z","timestamp":1747148393000},"page":"105792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["CD47 expression in classic follicular lymphoma is associated with event-free survival"],"prefix":"10.1016","volume":"158","author":[{"given":"Ayako","family":"Kume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheren","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Colace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Mahe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.humpath.2025.105792_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00277-017-3151-2","article-title":"Transformed follicular lymphoma","volume":"97","author":"Fischer","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.humpath.2025.105792_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jpm11020152","article-title":"Targeted treatment of follicular lymphoma","volume":"11","author":"Nath","year":"2021","journal-title":"J Personalized Med"},{"key":"10.1016\/j.humpath.2025.105792_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100992","article-title":"Follicular lymphoma: the long and winding road leading to your cure?","volume":"57","author":"Gordon","year":"2023","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.humpath.2025.105792_bib4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","article-title":"Macrophages as mediators of tumor immunosurveillance","volume":"31","author":"Jaiswal","year":"2010","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105792_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \"don't eat me\" signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.humpath.2025.105792_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.humpath.2025.105792_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103014","article-title":"CD47: the next checkpoint target for cancer immunotherapy","volume":"152","author":"Feng","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2025.105792_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.humpath.2025.105792_bib9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2025.105792_bib10","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2025.105792_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/aqaf018","article-title":"Expression of CD47 protein in hematolymphoid neoplasms: implications for CD47-mediated cancer immunotherapy","author":"Zhang","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2025.105792_bib12","article-title":"Follicular lymphoma","volume":"vol. 11","author":"Xerri","year":"2024"},{"key":"10.1016\/j.humpath.2025.105792_bib13","doi-asserted-by":"crossref","first-page":"D871","DOI":"10.1093\/nar\/gkm861","article-title":"The Stanford tissue microarray database","volume":"36","author":"Marinelli","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.humpath.2025.105792_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.humpath.2025.105792_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.humpath.2018.06.034","article-title":"Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies","volume":"82","author":"Devereaux","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105792_bib16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hon.2768","article-title":"Clinicopathological analysis of immunohistochemical expression of CD47 and SIRP\u03b1 in adult T-cell leukemia\/lymphoma","volume":"38","author":"Yanagida","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.humpath.2025.105792_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2025.105792_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1373\/clinchem.2007.096032","article-title":"Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions","volume":"54","author":"Leeflang","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.humpath.2025.105792_bib19","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/stem.2068","article-title":"p38\u03b3 MAPK is a therapeutic target for triple-negative breast cancer by stimulation of cancer stem-like cell expansion","volume":"33","author":"Qi","year":"2015","journal-title":"Stem Cell"},{"key":"10.1016\/j.humpath.2025.105792_bib20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3892\/ol.2022.13565","article-title":"Pan-cancer analysis supports MAPK12 as a potential prognostic and immunotherapeutic target in multiple tumor types, including in THCA","volume":"24","author":"Wang","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2025.105792_bib21","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1007\/s12094-024-03515-3","article-title":"A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma","volume":"26","author":"Liu","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.humpath.2025.105792_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-015-1840-6","article-title":"Mantle cell lymphoma--a spectrum from indolent to aggressive disease","volume":"468","author":"Sander","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2025.105792_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2025.105792_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: a translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2025.105792_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02603-9","article-title":"Molecular landscape of distinct follicular lymphoma histologic grades: insights from genomic and transcriptome analyses","author":"Sun","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2025.105792_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-019-0246-0","article-title":"SIRP\u03b1 expression delineates subsets of intratumoral monocyte\/macrophages with different functional and prognostic impact in follicular lymphoma","volume":"9","author":"Chen","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2025.105792_bib27","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105792_bib28","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/bloodadvances.2022007104","article-title":"SIRP\u03b1+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab","volume":"6","author":"Marques-Piubelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2025.105792_bib29","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2025.105792_bib30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2025.105792_bib31","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/cancers14092158","article-title":"Unveiling the role of the tumor microenvironment in the treatment of follicular lymphoma","volume":"14","author":"Blanco","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:15:07Z","timestamp":1748020507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"alternative-id":["S0046817725000796"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105792","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD47 expression in classic follicular lymphoma is associated with event-free survival","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105792"}}